We are live on
!
Find out more
AG
Aperio Group Portfolio holdings
AUM
$33.8B
1-Year Est. Return
31.46%
This Fund
S&P 500
This Quarter
Est. Return
+9.4%
1 Year Est. Return
+31.46%
3 Year Est. Return
+70.41%
5 Year Est. Return
+146.02%
10 Year Est. Return
–
AUM
$27.8B
AUM Growth
+$2.54B
(+10%)
Cap. Flow
+$477M
Cap. Flow
% of AUM
1.71%
Top 10 Holdings %
Top 10 Hldgs %
17.19%
Holding
2,397
New
92
Increased
1,264
Reduced
960
Closed
73
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$37.3M |
| 2 |
Johnson & Johnson
JNJ
|
+$35.5M |
| 3 |
Verizon
VZ
|
+$26.4M |
| 4 |
Truist Financial
TFC
|
+$26.1M |
| 5 |
CTXS
Citrix Systems Inc
CTXS
|
+$18.7M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CELG
Celgene Corp
CELG
|
+$53.1M |
| 2 |
STI
SunTrust Banks, Inc.
STI
|
+$25.3M |
| 3 |
CHL
China Mobile Limited
CHL
|
+$16.9M |
| 4 |
CUK
Carnival PLC
CUK
|
+$15M |
| 5 |
WBK
Westpac Banking Corporation
WBK
|
+$14.5M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 20.1% |
| 2 | Financials | 16.78% |
| 3 | Healthcare | 13.34% |
| 4 | Consumer Discretionary | 9.48% |
| 5 | Communication Services | 8.87% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1626
Nutanix
NTNX
$16B
| $704K | ﹤0.01% |
22,522
+3,222
| +17% | +$95.1K |
|
1627
Oil States International
OIS
$488M
| $704K | ﹤0.01% |
43,191
+3,949
| +10% | +$60K |
|
1628
V2X
VVX
$2.83B
| $702K | ﹤0.01% |
13,681
-928
| -6% | -$44.8K |
|
1629
Middlesex Water
MSEX
$1.07B
| $700K | ﹤0.01% |
11,007
-3,253
| -23% | -$206K |
|
|
NUVA
1630
DELISTED
NuVasive, Inc.
NUVA
| $700K | ﹤0.01% |
9,045
+358
| +4% | +$25.3K |
|
1631
RB Global
RBA
$20.4B
| $695K | ﹤0.01% |
16,175
+1,823
| +13% | +$75.9K |
|
|
ECHO
1632
EchoStar
ECHO
$24.4B
| $695K | ﹤0.01% |
16,040
+4,289
| +36% | +$172K |
|
1633
Phibro Animal Health
PAHC
$1.47B
| $694K | ﹤0.01% |
27,928
+9,506
| +52% | +$221K |
|
1634
US Physical Therapy
USPH
$1.2B
| $694K | ﹤0.01% |
6,069
-853
| -12% | -$106K |
|
1635
Great Southern Bancorp
GSBC
$874M
| $693K | ﹤0.01% |
10,937
-340
| -3% | -$20.6K |
|
1636
Patrick Industries
PATK
$2.74B
| $688K | ﹤0.01% |
19,686
+531
| +3% | +$17.3K |
|
1637
Westamerica Bancorp
WABC
$1.38B
| $688K | ﹤0.01% |
10,149
-155
| -2% | -$10.1K |
|
|
TRTN
1638
DELISTED
Triton International Limited
TRTN
| $688K | ﹤0.01% |
17,110
-237
| -1% | -$8.77K |
|
1639
Par Pacific Holdings
PARR
$4.31B
| $686K | ﹤0.01% |
29,497
-959
| -3% | -$22.9K |
|
|
LBAI
1640
DELISTED
Lakeland Bancorp Inc
LBAI
| $682K | ﹤0.01% |
39,232
-3,037
| -7% | -$50K |
|
1641
National Presto Industries
NPK
$870M
| $681K | ﹤0.01% |
7,705
-914
| -11% | -$79.5K |
|
1642
Enterprise Products Partners
EPD
$82.3B
| $678K | ﹤0.01% |
24,088
-880
| -4% | -$23.9K |
|
1643
FormFactor
FORM
$8.28B
| $678K | ﹤0.01% |
26,118
+1,638
| +7% | +$36.9K |
|
1644
HUTCHMED
HCM
$1.93B
| $678K | ﹤0.01% |
27,053
+10,951
| +68% | +$240K |
|
1645
Wabash National
WNC
$512M
| $678K | ﹤0.01% |
46,144
+432
| +0.9% | +$6.42K |
|
1646
Acadia Healthcare
ACHC
$2.76B
| $677K | ﹤0.01% |
20,365
-4,121
| -17% | -$129K |
|
1647
Encore Capital Group
ECPG
$2.02B
| $677K | ﹤0.01% |
19,153
-729
| -4% | -$25.5K |
|
|
JCAP
1648
DELISTED
Jernigan Capital, Inc.
JCAP
| $677K | ﹤0.01% |
35,378
+16,908
| +92% | +$311K |
|
1649
Fabrinet
FN
$15.6B
| $676K | ﹤0.01% |
10,421
+482
| +5% | +$27.9K |
|
|
SAGE
1650
DELISTED
Sage Therapeutics
SAGE
| $674K | ﹤0.01% |
9,329
+1,793
| +24% | +$221K |
|
Similar funds
OU
CTA
GAM
CCI
SWM
LCM
HCMNY
BII
Aperio Group's Q4 2019 Portfolio in Review
As of Q4 2019, Aperio Group held 2,397 positions worth $27.8B, up 10% from $25.3B the previous quarter. Its ten largest holdings account for 17% of the portfolio.
Aperio Group's Q4 2019 filing shows 92 new, 1,264 increased, 960 reduced and 73 closed positions. Its largest new stake was Cerence: 67,887 shares worth $1.54M. The largest sale was Celgene Corp, an estimated $53.1M.
By sector, the portfolio is most concentrated in Technology at 20% of assets, up from 19% a quarter earlier, followed by Financials and Healthcare.
- Aperio Group's largest Q4 2019 buy was Cerence: 67,887 shares worth $1.54M.
- Aperio Group added most to Bristol-Myers Squibb in Q4 2019, an estimated $37.3M increase.
- Aperio Group's biggest Q4 2019 reduction was China Mobile Limited, cutting an estimated $16.9M.
- Aperio Group fully exited Celgene Corp in Q4 2019, selling an estimated $53.1M.
- Aperio Group's ten largest holdings make up 17% of its $27.8B portfolio in Q4 2019.
- Aperio Group opened 92 new positions and closed 73 in Q4 2019.
- Aperio Group's portfolio value rose 10% quarter-over-quarter to $27.8B.
Based on Aperio Group's 13F filing for Q4 2019, filed 13 Feb 2020.